Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's disease

World Journal of Gastroenterology

Volumn 21, Issue 8, 2015, Pages 2475-2482

  Yang, Bo Lin ^a   Chen, Yu Gen ^a   Gu, Yun Fei ^a   Chen, Hong Jin ^a   Sun, Gui Dong ^a   Zhu, Ping ^a   Shao, Wan Jin ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Anal fistula; Crohn's disease; Infliximab; Surgery

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; INFLIXIMAB; POTASSIUM; THALIDOMIDE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ANUS FISTULA; ARTICLE; BREATHING DISORDER; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COLORECTAL SURGERY; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; CYANOSIS; DEPRESSED BLOOD PRESSURE; DROWSINESS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HEALING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFUSION RELATED REACTION; MAINTENANCE THERAPY; MALE; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIANAL FISTULIZING CROHN DISEASE; POTASSIUM BLOOD LEVEL; PROSPECTIVE STUDY; RECTUM FISTULA; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT OUTCOME; CHINA; COMPLICATION; DRUG EFFECTS; MULTIMODALITY CANCER THERAPY; RECTAL FISTULA; TERTIARY CARE CENTER; TIME; WOUND HEALING; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; CHINA; COMBINED MODALITY THERAPY; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLIXIMAB; MAGNETIC RESONANCE IMAGING; MALE; PROSPECTIVE STUDIES; RECTAL FISTULA; TERTIARY CARE CENTERS; TIME FACTORS; TREATMENT OUTCOME; WOUND HEALING; YOUNG ADULT;

EID: 84923798019     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i8.2475     Document Type: Article

References (29)

1. Bissell AD. Localized Chronic Ulcerative Ileitis. Ann Surg 1934; 99: 957-966 [PMID: 17867210]
2. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-885 [PMID: 14985485 DOI: 10.1056/NEJMoa030815]
3. Ardizzone S, Porro GB. Perianal Crohn's disease: overview. Dig Liver Dis 2007; 39: 957-958 [PMID: 17723323 DOI: 10.1016/ j.dld.2007.07.152]
4. Chung W, Kazemi P, Ko D, Sun C, Brown CJ, Raval M, Phang T. Anal fistula plug and fibrin glue versus conventional treatment in repair of complex anal fistulas. Am J Surg 2009; 197: 604-608 [PMID: 19393353 DOI: 10.1016/j.amjsurg.2008.12.013]
5. Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, Hommes DW, Lochs H, Angelucci E, Cocco A, Vucelic B, Hildebrand H, Kolacek S, Riis L, Lukas M, de Franchis R, Hamilton M, Jantschek G, Michetti P, O'Morain C, Anwar MM, Freitas JL, Mouzas IA, Baert F, Mitchell R, Hawkey CJ. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 2006; 55 Suppl 1: I36-i58 [PMID: 16481630 DOI: 10.1136/gut.2005.081950c]
6. Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med 2001; 135: 906-918 [PMID: 11712881 DOI: 10.7326/0003-4819-135-10-2 00111200-00011]
7. Orlando A, Colombo E, Kohn A, Biancone L, Rizzello F, Viscido A, Sostegni R, Benazzato L, Castiglione F, Papi C, Meucci G, Riegler G, Mocciaro F, Cassinotti A, Cosintino R, Geremia A, Morselli C, Angelucci E, Lavagna A, Rispo A, Bossa F, Scimeca D, Cottone M. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study. Dig Liver Dis 2005; 37: 577-583 [PMID: 15886081 DOI: 10.1016/j.dld.2005.01.019]
8. D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, Feagan B, Sandborn WJ, Colombel JF, Travis S. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106: 199-212; quiz 213 [PMID: 21045814 DOI: 10.1038/ ajg.2010.392]
9. Regueiro M, Mardini H. Treatment of perianal fistulizing Crohn' s disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 2003; 9: 98-103 [PMID: 12769443 DOI: 10.1097/00054725-200303000-00003]
10. Topstad DR, Panaccione R, Heine JA, Johnson DR, MacLean AR, Buie WD. Combined seton placement, infliximab infusion, and maintenance immunosuppressives improve healing rate in fistulizing anorectal Crohn's disease: a single center experience. Dis Colon Rectum 2003; 46: 577-583 [PMID: 12792431 DOI: 10.1007/ s10350-004-6611-4]
11. Gaertner WB, Decanini A, Mellgren A, Lowry AC, Goldberg SM, Madoff RD, Spencer MP. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas? Dis Colon Rectum 2007; 50: 1754-1760 [PMID: 17899271 DOI: 10.1007/ s10350-007-9077-3]
12. Sciaudone G, Di Stazio C, Limongelli P, Guadagni I, Pellino G, Riegler G, Coscione P, Selvaggi F. Treatment of complex perianal fistulas in Crohn disease: Infliximab, surgery or combined approach. Can J Surg 2010; 53: 299-304 [PMID: 20858373]
13. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn's disease activity index. National Cooperative Crohn' s Disease Study. Gastroenterology 1976; 70: 439-444 [PMID: 1248701]
14. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol 1995; 20: 27-32 [PMID: 7884173 DOI: 10.1097/00004836-199501000-00008]
15. van Koperen PJ, Safiruddin F, Bemelman WA, Slors JF. Outcome of surgical treatment for fistula in ano in Crohn's disease. Br J Surg 2009; 96: 675-679 [PMID: 19434701 DOI: 10.1002/bjs.6608]
16. Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum 2002; 45: 771-775 [PMID: 12072629 DOI: 10.1007/ s10350-004-6296-8]
17. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405 [PMID: 10228190 DOI: 10.1056/ NEJM199905063401804]
18. Ng SC, Plamondon S, Gupta A, Burling D, Swatton A, Vaizey CJ, Kamm MA. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. Am J Gastroenterol 2009; 104: 2973-2986 [PMID: 19755971 DOI: 10.1038/ajg.2009.509]
19. Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006; 49: 1837-1841 [PMID: 17041753 DOI: 10.1007/s10350-006-0656-5]
20. Tanaka S, Matsuo K, Sasaki T, Nakano M, Sakai K, Beppu R, Yamashita Y, Maeda K, Aoyagi K. Clinical advantages of combined seton placement and infliximab maintenance therapy for perianal fistulizing Crohn's disease: when and how were the seton drains removed? Hepatogastroenterology 2010; 57: 3-7 [PMID: 20422862]
21. Hotokezaka M, Ikeda T, Uchiyama S, Tsuchiya K, Chijiiwa K. Results of seton drainage and infliximab infusion for complex anal Crohn's disease. Hepatogastroenterology 2011; 58: 1189-1192 [PMID: 21937376 DOI: 10.5754/hge09586]
22. Leombruno JP, Nguyen GC, Grootendorst P, Juurlink D, Einarson T. Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis. Pharmacoepidemiol Drug Saf 2011; 20: 838-848 [PMID: 21688345 DOI: 10.1002/ pds.2132]
23. Lémann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L, Bourreille A, Sobahni I, Colombel JF. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 1054-1061 [PMID: 16618399 DOI: 10.1053/j.gastro.2006.02.014]
24. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-869 [PMID: 15825070 DOI: 10.1053/j.gastro.2005.01.048]
25. Zabana Y, Domènech E, Mañosa M, Garcia-Planella E, Bernal I, Cabré E, Gassull MA. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ther 2010; 31: 553-560 [PMID: 20002026 DOI: 10.1111/j.1365-2036.2009.04206.x]
26. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, Henckaerts L, Van Assche G, Vermeire S, Rutgeerts P. Longterm safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58: 501-508 [PMID: 18832524 DOI: 10.1136/gut.2008.163642]
27. Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, Rutgeerts P, Tang LK, Cornillie FJ, Sandborn WJ. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014; 63: 88-95 [PMID: 23974954 DOI: 10.1136/ gutjnl-2013-304984]
28. Zabana Y, Domènech E, San Román AL, Beltrán B, Cabriada JL, Saro C, Araméndiz R, Ginard D, Hinojosa J, Gisbert JP, Mañosa M, Cabré E, Gassull MA. Tuberculous chemoprophylaxis requirements and safety in inflammatory bowel disease patients prior to anti-TNF therapy. Inflamm Bowel Dis 2008; 14: 1387-1391 [PMID: 18452206 DOI: 10.1002/ibd.20496]
29. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-630 [PMID: 16678077 DOI: 10.1016/j.cgh.2006.03.002]